Challenges in initiating antiretroviral therapy in 2010

摘要: Many clinical trials have shown that initiating antiretroviral therapy (ART) at higher rather than lower CD4 T cell-positive counts results in survival benefit. Early treatment can help prevent end-organ damage associated with HIV replication and decrease infectivity. The mainstay of is either a non-nucleoside reverse transcriptase inhibitor or ritonavir-boosted protease combination two nucleoside inhibitors. While effective combating HIV, ART produce adverse alterations lipid parameters, some studies suggesting relationship between anti-retroviral agents cardiovascular disease. As the HIV-positive population ages, issues such as hypertension diabetes must be taken into account when ART. Adhering to difficult; however, nonoptimal adherence result development resistance; thus, drug characteristics patient’s preparedness begin considered. Reducing pill burden through use fixed-dose combinations facilitate adherence.